CP
Caligan Partners Portfolio holdings
AUM
$515M
This Quarter Return
+50.03%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$297M
AUM Growth
+$297M
(+52%)
Cap. Flow
+$23.5M
Cap. Flow
% of AUM
7.91%
Top 10 Holdings %
Top 10 Hldgs %
99.8%
Holding
13
New
–
Increased
3
Reduced
3
Closed
1
Top Buys
| 1 |
Liquidia Corp
LQDA
|
$13.4M |
| 2 |
Agios Pharmaceuticals
AGIO
|
$9.73M |
| 3 |
Y-mAbs Therapeutics
YMAB
|
$6.99M |
Top Sells
| 1 |
Evolus
EOLS
|
$3.85M |
| 2 |
Standard BioTools
LAB
|
$1.28M |
| 3 |
Verrica Pharmaceuticals
VRCA
|
$1.01M |
| 4 |
ADMA Biologics
ADMA
|
$562K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Liquidia Corp
LQDA
$2.38B
| $125M | 42.03% |
10,360,945
+1,117,318
| +12% | +$13.4M |
|
|
ALIM
2
DELISTED
Alimera Sciences, Inc.
ALIM
| $72.7M | 24.53% |
16,835,154
| – | – |
|
3
Anika Therapeutics
ANIK
$135M
| $24.5M | 8.26% |
1,081,360
| – | – |
|
4
Exelixis
EXEL
$10.1B
| $21.8M | 7.37% |
910,730
| – | – |
|
|
5
Standard BioTools
LAB
$481M
| $15.6M | 5.25% |
7,042,413
-580,000
| -8% | -$1.28M |
|
|
6
Evolus
EOLS
$494M
| $13.9M | 4.68% |
1,317,856
-365,980
| -22% | -$3.85M |
|
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $9.84M | 3.32% |
441,833
+437,000
| +9,042% | +$9.73M |
|
|
8
Y-mAbs Therapeutics
YMAB
$388M
| $7.15M | 2.41% |
1,048,425
+1,025,104
| +4,396% | +$6.99M |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $3.64M | 1.23% |
183,064
| – | – |
|
|
10
ADMA Biologics
ADMA
$4.12B
| $2.14M | 0.72% |
473,087
-124,426
| -21% | -$562K |
|
|
SCTL
11
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $592K | 0.2% |
1,689,768
| – | – |
|
|
12
Verrica Pharmaceuticals
VRCA
$52.8M
| – | – |
-259,593
| Closed | -$1.01M |
|
|
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
0
| – | – |
|